Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells 12,025 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) Director James R. Tobin sold 12,025 shares of the firm's stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $125.05, for a total transaction of $1,503,726.25. Following the completion of the sale, the director now owns 193,146 shares of the company's stock, valued at $24,152,907.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

TransMedics Group Stock Performance

NASDAQ TMDX traded down $5.37 during mid-day trading on Tuesday, reaching $127.28. 917,324 shares of the stock were exchanged, compared to its average volume of 770,717. The business's 50 day moving average is $87.41 and its 200-day moving average is $78.57. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $132.96. The company has a market capitalization of $4.19 billion, a P/E ratio of -374.35 and a beta of 1.87.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The company had revenue of $96.90 million during the quarter, compared to analysts' expectations of $83.78 million. During the same quarter in the prior year, the firm posted ($0.08) EPS. TransMedics Group's quarterly revenue was up 132.9% compared to the same quarter last year. On average, equities research analysts forecast that TransMedics Group, Inc. will post 0.62 EPS for the current fiscal year.

Analysts Set New Price Targets

TMDX has been the subject of a number of recent analyst reports. Morgan Stanley raised their price objective on TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 28th. Oppenheimer upped their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the company an "outperform" rating in a research note on Wednesday, May 1st. Piper Sandler reissued an "overweight" rating and set a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a report on Wednesday, May 1st. Canaccord Genuity Group increased their price objective on TransMedics Group from $102.00 to $117.00 and gave the company a "buy" rating in a report on Wednesday, May 1st. Finally, TD Cowen upped their price objective on shares of TransMedics Group from $100.00 to $130.00 and gave the company a "buy" rating in a report on Wednesday, May 1st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $119.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC increased its position in shares of TransMedics Group by 42.5% during the third quarter. FMR LLC now owns 4,714,870 shares of the company's stock worth $258,139,000 after purchasing an additional 1,407,171 shares in the last quarter. Eventide Asset Management LLC grew its holdings in shares of TransMedics Group by 1,271.7% during the third quarter. Eventide Asset Management LLC now owns 925,356 shares of the company's stock worth $50,663,000 after buying an additional 857,895 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in shares of TransMedics Group in the fourth quarter valued at about $35,804,000. Wasatch Advisors LP purchased a new position in shares of TransMedics Group in the first quarter worth about $32,162,000. Finally, Bank of New York Mellon Corp boosted its position in TransMedics Group by 91.4% during the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company's stock worth $41,615,000 after acquiring an additional 363,012 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.